Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes
ConditionType 2 Diabetes
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorYanbing Li
About this trial
This study is a multicenter, prospective, non-interventional real-world study to evaluate the clinical outcomes of biweekly cofrogliptin versus daily linagliptin as an add-on therapy in Chinese adult T2D patients.
Eligibility criteria
Qualifiers
Sign the informed consent form.
Aged ≥18 years.
Diagnosed with type 2 diabetes mellitus (meeting the 1999 WHO diagnostic criteria).
Recently tested HbA1c 7%-9% and FPG ≤11 mmol/L, with stable treatment using insulin ± OADs for at least 12 weeks prior to enrollment. Insulin regimens are limited to: basal insulin once daily or once weekly, premixed insulin once or twice daily, or IDegAsp once or twice daily. OAD classes are limited to metformin, SGLT2 inhibitors, and α-glucosidase inhibitors and with no more than three agents in total.
Disqualifiers
Allergic to the study drug.
Diagnosed with type 1 diabetes.
Unable to comply with study-specific procedures.
Current or planned pregnant, or currently breastfeeding.
Trial design
Treatments tested in this trial
- Cofrogliptin add to insulin
- Linagliptin add to insulin
Treatment groups
594 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yanbing Li
Lead sponsor
Sun Yat-sen University
Sponsor institution
Source ClinicalTrials.gov